Skip to main content
HR 7085 118th Congress House Government Operations and Politics Asia China Europe Health technology, devices, supplies Iran Middle East North Korea Public contracts and procurement Russia

BIOSECURE Act

Introduced: January 25, 2024 See on congress.gov
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 25, 2024
Referred to the House Committee on Oversight and Accountability.
Jan 25, 2024
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

BIOSECURE Act

This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.

Specifically, the bill prohibits executive agencies from (1) procuring or obtaining any biotechnology equipment or service produced or provided by a biotechnology company of concern, or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.

A biotechnology company of concern includes BGI, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of such entities, and any entity that

  • is subject to the jurisdiction, direction, control, or operates on behalf of the government of a foreign adversary;
  • is involved in the manufacturing, distribution, provision, or procurement of a biotechnology equipment or service; and
  • poses a risk to U.S. national security based on specified activities.

Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.

The Office of Management and Budget must develop and periodically update a list of the entities that constitute biotechnology companies of concern.

What's happening now January 25, 2024

Referred to the House Committee on Oversight and Accountability.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 7085: BIOSECURE Act. 118th Congress. Open America. https://openamerica.io/bill/118-HR-7085/
MLA
"H.R. 7085: BIOSECURE Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-7085/.
Bluebook (legal)
H.R. 7085, 118th Cong. (2026), https://openamerica.io/bill/118-HR-7085/.
Markdown link
[H.R. 7085: BIOSECURE Act](https://openamerica.io/bill/118-HR-7085/)
Report a problem